Literature DB >> 18055844

Ontogeny of the eotaxins in human lung.

Kathleen J Haley1, Mary E Sunday, Yolanda Porrata, Colleen Kelley, Anne Twomey, Aliakbar Shahsafaei, Benjamin Galper, Larry A Sonna, Craig M Lilly.   

Abstract

The ontogeny of the C-C chemokines eotaxin-1, eotaxin-2, and eotaxin-3 has not been fully elucidated in human lung. We explored a possible role for eotaxin in developing lung by determining the ontogeny of eotaxin-1 (CCL11), eotaxin-2 (CCL24), eotaxin-3 (CCL26), and the eotaxin receptor, CCR3. We tested discarded surgical samples of developing human lung tissue using quantitative RT-PCR (QRT-PCR) and immunostaining for expression of CCL11, CCL24, CCL26, and CCR3. We assessed possible functionality of the eotaxin-CCR3 system by treating lung explant cultures with exogenous CCL11 and analyzing the cultures for evidence of changes in proliferation and activation of ERK1/2, a signaling pathway associated with CCR3. QRT-PCR analyses of 22 developing lung tissue samples with gestational ages 10-23 wk demonstrated that eotaxin-1 mRNA is most abundant in developing lung, whereas mRNAs for eotaxin-2 and eotaxin-3 are minimally detectable. CCL11 mRNA levels correlated with gestational age (P < 0.05), and immunoreactivity was localized predominantly to airway epithelial cells. QRT-PCR analysis detected CCR3 expression in 16 of 19 developing lung samples. Supporting functional capacity in the immature lung, CCL11 treatment of lung explant cultures resulted in significantly increased (P < 0.05) cell proliferation and activation of the ERK signaling pathway, which is downstream from CCR3, suggesting that proliferation was due to activation of CCR3 receptors by CCL11. We conclude that developing lung expresses the eotaxins and functional CCR3 receptor. CCL11 may promote airway epithelial proliferation in the developing lung.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055844     DOI: 10.1152/ajplung.00086.2007

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  7 in total

1.  Increased CCL24/eotaxin-2 with postnatal ozone exposure in allergen-sensitized infant monkeys is not associated with recruitment of eosinophils to airway mucosa.

Authors:  Debbie L Chou; Joan E Gerriets; Edward S Schelegle; Dallas M Hyde; Lisa A Miller
Journal:  Toxicol Appl Pharmacol       Date:  2011-09-12       Impact factor: 4.219

2.  RUNX transcription factors: association with pediatric asthma and modulated by maternal smoking.

Authors:  Kathleen J Haley; Jessica Lasky-Su; Sara E Manoli; Lacey A Smith; Aliakbar Shahsafaei; Scott T Weiss; Kelan Tantisira
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-07-29       Impact factor: 5.464

3.  Cotinine in human placenta predicts induction of gene expression in fetal tissues.

Authors:  Carrie A Vyhlidal; Amanda K Riffel; Kathleen J Haley; Sunita Sharma; Hongying Dai; Kelan G Tantisira; Scott T Weiss; J Steven Leeder
Journal:  Drug Metab Dispos       Date:  2012-12-03       Impact factor: 3.922

4.  CCL26-targeted siRNA treatment of alveolar type II cells decreases expression of CCR3-binding chemokines and reduces eosinophil migration: implications in asthma therapy.

Authors:  Younes J Errahali; Equar Taka; Barack O Abonyo; Ann S Heiman
Journal:  J Interferon Cytokine Res       Date:  2009-04       Impact factor: 2.607

5.  Endotoxin inhalation alters lung development in neonatal mice.

Authors:  Katarina Kulhankova; Caroline L S George; Joel N Kline; Melissa Darling; Peter S Thorne
Journal:  Am J Ind Med       Date:  2012-05-10       Impact factor: 2.214

6.  Maternal smoking and the retinoid pathway in the developing lung.

Authors:  Sara E Manoli; Lacey A Smith; Carrie A Vyhlidal; Chang Hyeok An; Yolanda Porrata; Wellington V Cardoso; Rebecca M Baron; Kathleen J Haley
Journal:  Respir Res       Date:  2012-06-01

7.  Serum eotaxin-1 is increased in extremely-low-birth-weight infants with bronchopulmonary dysplasia or death.

Authors:  Jegen Kandasamy; Claire Roane; Alexander Szalai; Namasivayam Ambalavanan
Journal:  Pediatr Res       Date:  2015-08-13       Impact factor: 3.756

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.